Prostatype Genomics AB Logo

Prostatype Genomics AB

Provides a genetic test to assess prostate cancer aggressiveness and guide treatment choices.

PROGEN | ST

Overview

Corporate Details

ISIN(s):
SE0022574554 (+2 more)
LEI:
549300JO6MPCGPVHVU91
Country:
Sweden
Address:
Gustav III:s Boulevard 34, 169 73 Solna
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test, Prostatype®. The test is designed to provide a comprehensive assessment of the aggressiveness of diagnosed prostate cancer, particularly for patients with localized disease. It serves as a decision-making tool for clinicians and patients to help determine appropriate treatment strategies. The Prostatype® system uses existing biopsy tissue to analyze the expression of three key genes. This genetic data is combined with standard clinical parameters (PSA, Gleason Score, Tumor Stage) to calculate a proprietary P-score, which quantifies the risk of cancer mortality. By offering a more precise prognosis, the test aims to minimize both over- and under-treatment, thereby improving patient quality of life and saving healthcare resources.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Prostatype Genomics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Prostatype Genomics AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Prostatype Genomics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IMMUNIC, INC. Logo
Developing oral small molecule therapies for chronic inflammatory and autoimmune diseases.
United States of America
IMUX
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
IMMUPHARMA PLC Logo
Develops novel peptide therapeutics for autoimmune diseases like Lupus (SLE) and CIDP.
United Kingdom
IMM
IMMUTEP Ltd Logo
Developing LAG-3-based immunotherapies for cancer and autoimmune diseases.
United States of America
IMMP
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO
INBIOGEN CO.,Ltd Logo
Data mining, bioinformatics, and virtual assistance for the life sciences industry.
South Korea
101140
Incannex Healthcare Inc. Logo
Develops oral cannabinoid/psychedelic therapies for sleep apnea, arthritis & anxiety.
United States of America
IXHL
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhalation Sciences Sweden AB Logo
Inhalation research instruments and CRO services for preclinical pharma/biotech development.
Sweden
ISAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.